Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Orphanet	Ensembl
	HGNC	UniGene	Nucleotide	OMIM		UCSC

Home Page

FLASH GENE

Symbol

KRAS

contributors: mct - updated : 21-08-2016

HGNC name	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
HGNC id	6407

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

ASSOCIATED DISORDERS

corresponding disease(s)

NS3 , CFC5 , SMPS2

Other morbid association(s)

Type Gene Modification Chromosome rearrangement Protein expression Protein Function tumoral somatic mutation       in non small cell lung adenocarcinomas, in pancreatic cancer, in endometrial carcinoma (not in endometrial hyperplasia)and in thyroid cancer with poor prognosis tumoral somatic mutation       in MM and PPCL at an early stage, in rectal cancer and adenoma, and in colorectal tumors with poor prognosis tumoral somatic mutation       in high hyperdiploid childhood acute lymphoblastic leukemia tumoral somatic mutation       promotes colon cancer progression (mutation arise after loss of APC during colon cancer progression) tumoral somatic mutation       in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis tumoral somatic mutation     gain of function activating mutations in the KRAS gene impair the ability of the KRAS protein to switch between active and inactive states, leading to cell transformation and increased resistance to chemotherapy and biological therapies targeting epidermal growth factor receptor tumoral somatic mutation     gain of function activating KRAS mutations is significantly correlated to an upregulation of 13 genes among them DUSP4, a MAP-kinase phosphatase, and SMYD3 in colorectal cancer tumoral somatic mutation       in autoimmune lymphoproliferative syndrome constitutional     --low   depletion of KRAS promotes proteasome degradation of BIRC5 (PMID

Susceptibility

Variant & Polymorphism

Candidate gene
Marker
Therapy target
	System Type Disorder Pubmed cancer digestive colon importance of KRAS alterations as a potential therapeutic target for Colorectal cancer osteoarticular     RAS/ERK1/2 inhibition could be a potent strategy to treat RASopathies, including Noonan sdr cancer digestive pancreas therapy target in pancreatic ductal adenocarcinoma (PDAC)

ANIMAL & CELL MODELS